Physician profile
James Kim
NPI 1912195413
$1,127.65
in general payments reported to CMS, 2019-2025
9 companies · $153 in 2025
The $153 reported for 2025 was more than what 75% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $26.79 · 2021: $442 · 2022: $340 · 2023: $139 · 2024: $27.78 · 2025: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $319.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $319.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $868.26 | 2021-2025 | Proclaim |
| Saluda Medical Americas, INC. | $58.87 | 2025 | Evoke |
| Edwards Lifesciences Corporation | $42.53 | 2023 | Sapien 3 Ultra Resilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.19 | 2023-2025 | Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $28.29 | 2025 | Entyvio |
| La Jolla Pharmaceutical Company | $27.78 | 2024 | Giapreza |
| Portola Pharmaceuticals, LLC | $26.79 | 2020 | |
| Janssen Biotech, INC. | $19.03 | 2021 | |
| Stryker Corporation | $16.91 | 2025 | Ortholoc 2 Lapifuse |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.